Opportunities for Drug Repurposing of Serotonin Reuptake Inhibitors: Potential Uses in Inflammation, Infection, Cancer, Neuroprotection, and Alzheimer's Disease Prevention.
Pharmacopsychiatry
; 55(1): 24-29, 2022 Jan.
Article
in English
| MEDLINE | ID: covidwho-1556894
ABSTRACT
Serotonin reuptake inhibitors (SRIs) are safe and widely used for a variety of indications including depressive disorders, anxiety, and chronic pain. Besides inhibiting the serotonin transporter, these medications have broad-spectrum properties in many systems. Their roles have been studied in cancer, Alzheimer's disease, and infectious processes. The COVID-19 pandemic highlighted the importance of drug repurposing of medications already in use. We conducted a narrative review of current evidence and ongoing research on drug repurposing of SRIs, with a focus on immunomodulatory, antiproliferative, and neuroprotective activity. SRIs may have clinical use as repurposed agents for a wide variety of conditions including but not limited to COVID-19, Alzheimer's disease, and neoplastic processes. Further research, particularly randomized controlled trials, will be necessary to confirm the utility of SRIs for new indications.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Alzheimer Disease
/
COVID-19
/
Neoplasms
Type of study:
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
/
Reviews
Limits:
Humans
Language:
English
Journal:
Pharmacopsychiatry
Year:
2022
Document Type:
Article
Affiliation country:
A-1686-9620
Similar
MEDLINE
...
LILACS
LIS